I was referring to complete vs conditional MA. I thought Missling said they were going for “complete” MA through the centralized procedure, meaning we have more comprehensive data.
Did he? Can anyone confirm? Maybe I imagined it.
Complete Marketing Authorization (MA) and Conditional Marketing Authorization (CMA) are two different pathways for obtaining approval to market and sell medicinal products within the European Union (EU) and European Economic Area (EEA). Here's a comparison of the two:
1. **Complete Marketing Authorization (MA):**
- Process: Under the complete MA pathway, pharmaceutical companies submit comprehensive marketing authorization applications to regulatory authorities, such as the European Medicines Agency (EMA), for review and approval.
- Data Requirements: Companies are required to provide extensive data on the quality, safety, and efficacy of the medicinal product, including results from preclinical studies and clinical trials, manufacturing processes, and pharmacovigilance plans.
- Approval Criteria: The regulatory authority evaluates the application and assesses whether the medicinal product meets the necessary standards for safety, efficacy, and quality. If the criteria are met, the regulatory authority grants full marketing authorization, allowing the product to be marketed and sold in the EU/EEA.
- Conditions: Full marketing authorization is granted without specific conditions or obligations, although post-authorization surveillance and monitoring may be required.
2. **Conditional Marketing Authorization (CMA):**
- Process: Conditional marketing authorization is granted for medicinal products that address unmet medical needs and provide a significant benefit to patients, but for which comprehensive data are not yet available.
- Data Requirements: Companies must provide preliminary data on the quality, safety, and efficacy of the medicinal product, but additional confirmatory data may be required to support full approval.
- Approval Criteria: The regulatory authority evaluates the available data and assesses whether the benefit-risk balance justifies granting conditional marketing authorization. If the criteria are met, conditional marketing authorization is granted, allowing the product to be marketed and sold in the EU/EEA.
- Conditions: Conditional marketing authorization is granted with specific conditions or obligations, such as the requirement for the company to complete additional studies to confirm the product's efficacy and safety. Risk management measures and pharmacovigilance activities are also required to monitor the product's safety and effectiveness once it is on the market.
In summary, while both complete MA and conditional MA pathways allow medicinal products to be marketed and sold in the EU/EEA, they differ in terms of the data requirements, approval criteria, and conditions associated with marketing authorization. Conditional MA is intended for products that address unmet medical needs and provide a significant benefit to patients, but for which additional data are needed to support full approval.
AI
Market Data 
Markets 
